The original agreement signed between Cura and GeoPharma provided Cura the exclusive US distribution rights of GeoPharma’s patented oral Mucotrol wafer, which had received the FDA approval as a medical device.
The recent extension of the primary agreement allows for additional partners to be secured, proliferating the acceptance of Mucotrol in other regions of the world previously unexplored. The new aspect of the agreement embraces two new regional partners and allows for the dissemination of Mucotrol in India, Nepal, Bangladesh, Sri Lanka and South Korea.
GeoPharma’s Mucotrol is a concentrated oral gel wafer that was designed as a method of pain management for patients suffering from oral mucositis.
Mihir Taneja, CEO of GeoPharma, said: “The expansion of the Cura agreement to include additional worldwide partners is another example of the continued development of GeoPharma’s business plan. We are pleased that the Mucotrol product is in higher demand and expanding its customer base.”